Compare Novavax Inc (NVAX) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Novavax Inc trades at $12.73 (market cap $1.82B), while YieldMax Universe Fund of Option Income ETFs trades at $7.62 (market cap $364M). The key difference: Novavax Inc is far larger — about 5× YieldMax Universe Fund of Option Income ETFs's market cap, and Novavax Inc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and YieldMax Universe Fund of Option Income ETFs for 56 Days on average.
| NVAX | YMAX | |
|---|---|---|
Market Cap | $1.82B | $364M |
Volume | 6,198,505 | 1,181,378 |
Sector | Health | Income / Options Overlay |
52-Week High | $12.56 | $12.98 |
52-Week Low | $6.22 | $7.27 |
Typical Hold Time | 59 Days | 56 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
YMAX trades at $7.61, up 1.06% with a bearish technical outlook. The ETF shows persistent NAV erosion despite weekly distributions, with the share price declining 22.7% year-to-date. Recent portfolio adjustments and a 40%+ annualized yield highlight structural concerns about distribution sustainability. Technical indicators show bearish moving averages and neutral oscillators with support at $7 and resistance at $8.
The outlook remains cautious due to ongoing principal erosion and high fees. While the high yield attracts income investors, the fund-of-funds structure adds layered costs. Analyst sentiment is neutral to bearish, with concerns about long-term viability outweighing short-term income benefits. Key risks include distribution policy sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
